30 August 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Notice of Results and Investor Presentation via Investor Meet Company
Ondine Biomedical Inc. (LON: OBI) confirms it will be announcing its interim results for the six months ended 30 June 2023 on Monday, 25 September 2023.
Dr. Nicolas Loebel, Ondine's CTO and President, will provide a live presentation relating to the Interim Results via Investor Meet Company on 25 September 2023 at 4:30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Ondine Biomedical Inc. via:
https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
Investors who already follow Ondine Biomedical Inc. on the Investor Meet Company platform will automatically be invited.
| Ondine Biomedical Inc. |
|
| Carolyn Cross, CEO | +001 (604) 665 0555 |
|
|
|
| Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| |
|
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.